Galambos, Michael
Digestive Healthcare of Georgia Atlanta Georgia USA
3 papers on CoChat
Most cited papers
- Verified
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet
Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity
Cited by 1,277
- Verified
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study
Jones, D., Boudes, P. F., Swain, M. G., Bowlus, C. L., Galambos, M. R., Bacon, B. R., Doerffel, Y., Gitlin, N., Gordon, S. C., Odin, J. A., et al. (2017) · The Lancet Gastroenterology & Hepatology
Liver Diseases and ImmunityPeroxisome Proliferator-Activated Receptors
Cited by 191
- Verified
Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis
Mayo, M. J., Vierling, J. M., Bowlus, C. L., Levy, C., Hirschfield, G. M., Neff, G. W., Galambos, M. R., Gordon, S. C., Borg, B. B., Harrison, S. A., et al. (2024) · Alimentary Pharmacology & Therapeutics
Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms
Cited by 39
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free